DE69933776D1 - GABA B-REZEPTOR-SUBTYPEN GABA B-R1c UND GABA B-R2 UND DEREN HETERODIMERE - Google Patents

GABA B-REZEPTOR-SUBTYPEN GABA B-R1c UND GABA B-R2 UND DEREN HETERODIMERE

Info

Publication number
DE69933776D1
DE69933776D1 DE69933776T DE69933776T DE69933776D1 DE 69933776 D1 DE69933776 D1 DE 69933776D1 DE 69933776 T DE69933776 T DE 69933776T DE 69933776 T DE69933776 T DE 69933776T DE 69933776 D1 DE69933776 D1 DE 69933776D1
Authority
DE
Germany
Prior art keywords
gaba
gabab
receptor
heterodimers
types
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933776T
Other languages
English (en)
Other versions
DE69933776T2 (de
Inventor
Antony Barnes
Alan Wise
Hamilton Marshall
James Fraser
Helen White
Michael Foord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9819420.2A external-priority patent/GB9819420D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69933776D1 publication Critical patent/DE69933776D1/de
Application granted granted Critical
Publication of DE69933776T2 publication Critical patent/DE69933776T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69933776T 1998-09-07 1999-09-03 GABA B-REZEPTOR-SUBTYPEN GABA B-R1c UND GABA B-R2 UND DEREN HETERODIMERE Expired - Lifetime DE69933776T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9819420.2A GB9819420D0 (en) 1998-09-07 1998-09-07 Novel receptor
GB9819420 1998-09-07
US10367098P 1998-10-09 1998-10-09
US103670P 1998-10-09
PCT/GB1999/002918 WO2000014222A2 (en) 1998-09-07 1999-09-03 GABAB RECEPTOR SUBTYPES GABAB-R1c AND GABAB-R2 AND HETERODIMERS THEREOF

Publications (2)

Publication Number Publication Date
DE69933776D1 true DE69933776D1 (de) 2006-12-07
DE69933776T2 DE69933776T2 (de) 2008-01-03

Family

ID=26314336

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933776T Expired - Lifetime DE69933776T2 (de) 1998-09-07 1999-09-03 GABA B-REZEPTOR-SUBTYPEN GABA B-R1c UND GABA B-R2 UND DEREN HETERODIMERE

Country Status (7)

Country Link
EP (1) EP1109901B1 (de)
JP (1) JP2002524074A (de)
AT (1) ATE343634T1 (de)
AU (1) AU5639799A (de)
DE (1) DE69933776T2 (de)
ES (1) ES2275351T3 (de)
WO (1) WO2000014222A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044265A4 (de) * 1998-08-27 2002-10-29 Synaptic Pharma Corp Dna, die für ein gaba br2 polypeptid kodiert und deren verwendungen
JP4581277B2 (ja) * 2000-03-28 2010-11-17 味の素株式会社 非意図的行動抑制用医薬組成物、および、ランニングニューロン抑制物質の該医薬組成物製造のための使用
CA2413451A1 (en) * 2000-06-19 2001-12-27 Merck Frosst Canada & Co. Methods of identifying gabab receptor subtype-specific agonists
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
WO2005026208A2 (en) * 2003-09-12 2005-03-24 Janssen Pharmaceutica N.V. Chimeric gabab receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE290079T1 (de) * 1996-05-30 2005-03-15 Novartis Pharma Gmbh Metabotropische gaba(b) rezeptoren, rezeptoren- spezifische liganden und deren anwendungen
WO1999020751A1 (en) * 1997-10-17 1999-04-29 Synaptic Pharmaceutical Corporation Dna encoding a gababr2 polypeptide and uses thereof
EP1027374A1 (de) * 1997-10-27 2000-08-16 AstraZeneca AB Nukleotidsequenzen
CA2321193A1 (en) * 1998-02-05 1999-08-12 Merck & Co., Inc. Novel gabab receptor dna sequences
EP0937777A3 (de) * 1998-02-20 1999-11-24 Smithkline Beecham Plc GABA Rezeporen und deren Anwendungen
WO1999042603A1 (en) * 1998-02-20 1999-08-26 Smithkline Beecham Corporation GABAB-R2a, A 7TM RECEPTOR
WO1999051636A2 (en) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. Gaba b receptor
IL138747A0 (en) * 1998-04-03 2001-10-31 Nps Pharma Inc G-protein fusion receptors and chimeric gabab receptors
AUPP438498A0 (en) * 1998-06-29 1998-07-23 Garvan Institute Of Medical Research Novel Gaba-B receptor

Also Published As

Publication number Publication date
ATE343634T1 (de) 2006-11-15
WO2000014222A3 (en) 2000-07-06
EP1109901B1 (de) 2006-10-25
JP2002524074A (ja) 2002-08-06
EP1109901A2 (de) 2001-06-27
WO2000014222A2 (en) 2000-03-16
AU5639799A (en) 2000-03-27
ES2275351T3 (es) 2007-06-01
DE69933776T2 (de) 2008-01-03

Similar Documents

Publication Publication Date Title
ATE377606T1 (de) Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
DE69942622D1 (de) Nukleinsäuren, die für einen an ein G-Protein gekoppelten, an der sensorischen Transduktion beteiligten Rezeptor kodieren
ATE466030T1 (de) Neues screening-verfahren
EA200400816A1 (ru) Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
YU34898A (sh) Antagonisti ccr-3 receptora
CY1107339T1 (el) Mu-1, μελος της οικογενειας υποδοχεα κυτοκινης
DK1405083T3 (da) Naturlig ligand af GPCR ChemR23 og anvendelser deraf
DE69933776D1 (de) GABA B-REZEPTOR-SUBTYPEN GABA B-R1c UND GABA B-R2 UND DEREN HETERODIMERE
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
TR200102317T2 (tr) Viskozite stabilitesi yüksek naylon-6 üretimi.
BR9814161A (pt) Método de sìntese de pirrolamidas
ATE511644T1 (de) Neues screening-verfahren
ATE494550T1 (de) Neues screening-verfahren
WO2003082320A1 (fr) Nouveau procede de criblage
SE9804274D0 (sv) Novel receptor
TW200504212A (en) Human G protein-coupled receptor and modulators thereof for the treatment of inflammatory disorders
DK1066250T3 (da) En konvergent syntese af alpha-aryl-beta-ketonitriler
MX9302841A (es) Subunidades de receptores nmda, un procedimiento para su preparacion y su empleo.
BRPI0412255A (pt) tratamento da disfunção sexual masculina
ATE375364T1 (de) G-protein gekoppelter rezeptor
ATE445159T1 (de) Neues screening-verfahren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition